Medication adherence is essential to successful treatment of HIV/AIDS. Maintaining high adherence will likely prove a major challenge in Africa --just as it has in developed nations. Despite early reports suggesting that adherence would not pose a major barrier to treatment success, more recent research shows that adherence rates in Africa are quite variable and often poor. Given the large number of patients whose disease will progress if adherence is suboptimal, research is urgently needed to determine patient-level behavioral barriers to adherence and the most effective and appropriate methods for assessing adherence in African cohorts.
Introduction
While highly active combination antiretroviral therapy (HAART) dramatically reduces morbidity and mortality due to AIDS [1, 2] , these benefits critically depend on patients achieving and maintaining high levels of medication adherence. Missing more than 5-10% of doses is linked to incomplete suppression of viral replication, declining CD4 cell counts [3] [4] [5] clinical progression to AIDS or death [3, [6] [7] [8] , and the development and spread of antiretroviral drug-resistant HIV [9] [10] [11] [12] [13] . Just as human behavior is the key to preventing HIV infection, behavior is arguably the most important determinant of successful treatment outcomes [3, [5] [6] [7] [8] 14, 15] .
The unprecedented multilateral support through the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, TB and Malaria (GFATM) are necessary to alleviate structural barriers to treatment in low resource countries and to expand access to essential drugs. However, even if all structural barriers to HAART are removed, HAART programs can still fail if they do not adequately address behavioral factors influencing adherence. Notwithstanding several encouraging reports on African populations [5, 16, 17] , recent reports show that HAART adherence and clinical success rates vary widely across sub-Saharan programs, and offer no justification for complacency at this stage in our response to the global HIV/AIDS pandemic.
The challenge of measuring adherence
Medication adherence research from developed nations makes clear how difficult adherence is to measure Table 1 . Summary of methods for assessing adherence.
Method

Advantages
Disadvantages
Direction of potential bias
Comments
Physician's assessment Simple
Subjective
No particular bias
De facto manner in which adherence is usually assessed Cheap Inaccurate Inaccurate both for predicting adherence and non-adherence [31] [32] [33] Requires no structured tool Adherence estimates may affect/be affected by physician-patient relationship One study noted that physicians correctly rated their patients' adherence 40% of the time [3] Patient self-report
Simple
Subjective
Overestimates adherence Currently the most widely-used adherence measure
Cheap
Inaccurate
More accurate for predicting non-adherence than high adherence [20] Allows qualitative assessment of adherence Accuracy can be affected by: poor patient recall, failure to recognize mistimed doses, dose missed over holidays/weekends as non-adherence, lack of patient candor Encompasses a variety of techniques, including unstructured interviews, visual analog scales, and standardized questionnaires
One study found that patients recalled only 41% of documented visits, while 28% recalled visits that never occurred [34] One study found that of patients who denied missing any protease inhibitor doses, 50% had undetectable levels [35] Pill counts accurately. In the absence of directly observed therapy, levels of adherence can only be estimated by use of surrogate measures. Commonly used methods include pill counts, pharmacy refill records, drug level monitoring, electronic drug monitors (EDM), and various selfreporting tools, such as questionnaires and visual analog scales. Each method has clear advantages and disadvantages ( Table 1) .
Knowledge of the comparative accuracy of different surrogate measures is based mainly on research conducted in developed countries over the past decade. Arnsten et al.
reported mean HAART adherence rates of 79% by selfreport but only 53% by EDM. Moreover, patients whose EDM data indicated high adherence (above 90%) were far more likely to achieve undetectable viral load (UDVL) than patients self-reporting the same level of adherence [18] . Liu et al. concurrently compared several measures against patient UDVL rates [19] . Mean adherence using EDM was 63% versus 83% for pill count and 93% for selfreport. However, among patients who failed to achieve UDVL at 8 weeks, mean adherence was 87% for selfreport, 74% for pill count, but only 59% for EDM. In both these studies, the poor association between selfreport or pill counts and UDVL -compared with the relationship between EDM and UDVL -implied that they greatly overestimated true adherence. Similarly, a recently validated self-report instrument achieved 72% sensitivity and 91% specificity for detecting good (above 90%) adherence using EDM as the reference standard [20] . A simple interpretation of this finding is that skepticism is warranted when patients report high adherence, though patients should generally be believed when reporting poor adherence.
Trials of directly observed HAART provide additional evidence of the accuracy of EDM. Since adherence can be known precisely, the link between adherence levels and UDVL can be established with a high degree of confidence. One trial studied the effectiveness of azidothymidine/lamivudine/abacavir among HIV infected prisoners. Mean adherence was 94% with 85% of inmates achieving UDVL [21] . These results are remarkably similar to the relationship between UDVL and EDM-rated adherence: What is known about HAART adherence in Africa?
One of the earliest reports found high (above 90%) mean self-reported adherence and relatively high proportions (71%) achieving UDVL [5] . This attracted much attention in the scientific and lay press given earlier concerns about the feasibility of HAART in Africa [22] . Notably, the New York Times responded with a headline reading 'Africans Outdo US Patients in Following AIDS Therapy' [23] . However, the study's patients may not have represented a generalizable example as all were concurrently enrolled in ongoing randomized controlled trials, and would have benefited from the structural supports provided by the trial. Moreover, the analysis excluded the adherence data for 52 subjects (16% of the total) who abandoned HAART before completing 48 weeks of follow up. Average adherence for the overall group would certainly have been lower had these subjects been included.
That said, several more recent reports of African HAART programs, most of which were not part of clinical trials, also reported high levels of adherence. In general, most relied on self-reported adherence, followed small numbers of patients for short periods, or were cross-sectional analyses and thus could not comment on sustained adherence rates (see Table 2 ).
However, a growing number of programs have now reported mediocre or poor adherence, and in the few studies that reported longitudinal data, declining adherence over time ( Table 2 ). In Senegal, Laurent et al. noted that over 95% of their patients had adherence exceeding 80% after 1 month on therapy, but 18 months later only 80% of patients remained above that level. Concurrently, the proportion of their patients with UDVL fell from 79.6 to 59.3% [24] . In Cameroon, Akam reported that mean self-reported adherence was initially only 68% and declined further over time [25] .
Few studies compared multiple surrogate measures in parallel. Oyugi et al. measured adherence via self-report, pill count, visual analog score, and EDM, and found adherence levels at 24 weeks of 85, 86, 88, and 82%, respectively, implying a high degree of concordance between the various measures, and leading to speculation that the relationship between EDM and self-reported adherence in African cohorts might be tighter than was seen in US studies [26] . However, these rates only applied to the 46% (32/70) of their participants who completed 24 weeks of observation, and the investigators only reported aggregate UDVL rates. In contrast, Omes et al.
reported highly discordant levels of adherence between two forms of self-report: questionnaire and visual analog scale [27] . Neither study provided data on which surrogate marker best predicted UDVL, therefore precluding conclusions about their relative accuracy. In studies that did report both UDVL and measured adherence, the association was frequently poor. Eholié et al. in Côte d'Ivoire reported that 52% of their patients were poorly adherent, and that HIV was often detectable even among those reporting over 90% adherence [28] . A report from Durban, South African was perhaps most striking: with 100% of patients self-reporting 100% adherence, only 57% actually achieved UDVL [29] --a result highly reminiscent of US studies showing a significant disconnect between self-reported adherence and clinical success [18, 19] .
Where do we go from here?
Several observations emerge. First, reports that generalize about 'adherence rates in Africa' should be interpreted cautiously. A safer conclusion would be that adherence is proving to be highly challenging in African cohorts -just as it has for patients living in North America or Europe. We also question whether publication bias might lead results from less successful programs to go un-reported. Second, given growing doubts about the accuracy of self-reported adherence, some programs which appear to be successful may, in fact, be less so. Our interpretation of the limited data, notably those studies showing high self-reported adherence but low attainment of UDVL, [29, 30] is that self-report is proving to be as unreliable a measure of adherence in Africa as it has elsewhere [18, 19] . Third, external multinational funds should be allocated to supporting and studying adherence, and should not stop merely at the provision of test kits, basic training, and medications. Fourth, assuming successful models of adherence support can be found, it is uncertain whether they can be sustained with the oftenlimited support available from the public sector in many sub-Saharan countries. Notably, three of the lowest performing programs all appeared to have received little external technical or financial support through collaborations with foreign investigators or aid agencies. In contrast, the well-supported Médecins Sans Frontières (MSF) programs all included comprehensive adherence support mechanisms, and were among the most successful in terms of high reported adherence, low default rates, and high proportions of patients with UDVL. It would be extremely valuable to learn what aspects of MSF's adherence structures could be adapted cost-effectively and at scale in other settings.
These reports also help focus the research agenda for coming years. First and foremost, qualitative research into the behavioral reasons for patient non-adherence is urgently needed. The African adherence studies to date have all limited their scope to reporting adherence rates and occasionally population-level risk factors for non-adherence. Unfortunately, while epidemiologic studies are helpful at identifying 'Who is non-adherent?' they provide less insight into the more pressing question of 'Why?' a given patient chooses to adhere or not. Similarly, once a sufficient level of adherence is achieved, what are the behavioral factors that foster sustained adherence? Second, for programmatic evaluation, it is important to determine the most accurate and costeffective approach to measuring adherence in African populations. To provide a common point of comparison between studies and populations, we feel strongly that the relative accuracy of surrogate adherence measures should always be indexed against an external clinical gold standard. UDVL may be best suited for this role, though rising rates of resistance and other factors could lead to an underestimation of adherence rates over time. Another option would be drug level monitoring, though operationalizing this would no doubt prove enormously challenging.
We have learned much over the past decades about treating HIV infection in developed settings. However, because of the demanding and unforgiving nature of the disease and our dependence on human behavior to take these highly effective medications, it is essential that we both truly understand the local complexities of adherence behavior and can respond to it effectively. It is important that the scope of programs funded by large multinational programs (PEPFAR, GFATM) support investigation of these issues within the context of existing and future programs.
